5,494 results on '"Paszkiewicz A"'
Search Results
352. What a Woman Wants? Nancy Meyers’s The Intern
353. Genre on the Surface: Sofia Coppola’s Marie Antoinette
354. Repeat to Remake: Diablo Cody and Karyn Kusama’s Jennifer’s Body
355. Genre in the Margins: Kelly Reichardt’s Meek’s Cutoff
356. Genre, Authorship and Contemporary Women Filmmakers
357. Hollywood Transvestite: Kathryn Bigelow’s The Hurt Locker1
358. Desperately Seeking Wonder Women
359. Dielectric spectroscopy of novel bio-based aliphatic-aromatic block copolymers: Poly(butylene terephthalate)-b-poly(lactic acid)
360. Głos Gminy Łańcut. 2023, nr 3 (153) (marzec)
361. Głos Gminy Łańcut. 2023, nr 5 (155) (czerwiec)
362. Głos Gminy Łańcut. 2023, nr 4 (154) (kwiecień/maj)
363. Głos Gminy Łańcut. 2023, nr 2 (152) (luty)
364. Głos Gminy Łańcut. 2023, nr 1 (151) (styczeń)
365. The Journey of Cancer Cells to the Brain : Challenges and Opportunities
366. High-Power Test of Two Prototype X-band Accelerating Structures Based on SwissFEL Fabrication Technology
367. Social and economic determinants of the Wallachian settlement in Thessaloniki in the 19th and early 20th centuries
368. Tijana Vuković, Regaining the Yugoslav Heritage vs. Culture Crisis Regaining the Past. Yugoslav Legacy in the Period of Transition: The Case of Formal and Alternative Institutions of Art and Culture in Serbia at the End of the 20th and the Beginning of the 21st Century, Warsaw–Bellerive-sur-Allier, Wydawnictwo DiG 2022, pp. 343
369. Application of genetic algorithm to load balancing in networks with a homogeneous traffic flow
370. Rethinking commonality in refugee status determination in Europe: Legal geographies of asylum appeals
371. Richter transformation – retrospective treatment outcomes analysis in Polish Adult Leukemia Study Group.
372. Multifunctional clustering based on the LEACH algorithm for edge-cloud continuum ecosystem.
373. Sulphated TiO 2 Reduced by Ammonia and Hydrogen as an Excellent Photocatalyst for Bacteria Inactivation.
374. Stray aesthetic in the cinema of Andrea Arnold.
375. Recenzje: Tijana Vuković, Regaining the Yugoslav Heritage vs. Culture Crisis Regaining the Past. Yugoslav Legacy in the Period of Transition: The Case of Formal and Alternative Institutions of Art and Culture in Serbia at the End of the 20th and the Beginning of the 21st Century, Warsaw–Bellerive sur Allier, Wydawnictwo DiG 2022, ss. 343
376. Dapagliflozin prevents abdominal visceral and subcutaneous adipose tissue dysfunction in the insulin‐resistant canine model
377. New molecular targets in Hodgkin and Reed-Sternberg cells
378. Comparison of two swab types for recovery of Staphylococcus aureus and Candida auris from gloves and gowns
379. Selective targeting of pathogenic auto-reactive VH4–34 B cells with a rationally developed anti-VH4–34 antibody offers a new therapeutic approach for autoimmune disorders
380. Miniaturized Solid Phase Extraction techniques for different kind of pollutants analysis: State of the art and future perspectives – PART 1
381. Reusable passive sampler with carbon nanotubes for monitoring contaminants in wastewater: Application, regeneration and reuse
382. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study
383. Supplementary Figure 1 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
384. Supplementary Figure 5 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
385. Data from Targeting FACT Complex Suppresses Mammary Tumorigenesis in Her2/neu Transgenic Mice
386. Supplementary Material from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
387. Supplementary Figure S3 from Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells
388. Supplementary Figure Legends from Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells
389. Supplementary Figure 2 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
390. Supplementary Tables 1-2 from Targeting FACT Complex Suppresses Mammary Tumorigenesis in Her2/neu Transgenic Mice
391. Supplementary Figure 3 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
392. Supplemental Table 3 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
393. Supplemental Table 2 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
394. Supplemental Table 1 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
395. Supplementary Figure 4 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
396. Data from Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells
397. Supplementary Materials from Targeting FACT Complex Suppresses Mammary Tumorigenesis in Her2/neu Transgenic Mice
398. Supplementary Figure 1 from Targeting FACT Complex Suppresses Mammary Tumorigenesis in Her2/neu Transgenic Mice
399. Can photocatalysis help in the fight against COVID-19 pandemic?
400. Natural is not in it: Irony, Environment and Genre in Spoor (2017)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.